Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy
PepGen (NASDAQ: PEPG) Shares Phase 1 Clinical Trial Results of PGN-EDO51 Showing Positive Data in Treating Duchenne Muscular Dystrophy
PepGen, Inc. (NASDAQ: PEPG) is engaged as a clinical-stage biotechnology company, which is focused on the research and development of
PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments
BOSTON, June 16, 2022 (GLOBE NEWSWIRE) -- PepGen Inc. (“PepGen”), a clinical-stage biotechnology company advancing the next generation of oligonucleotide...
It’s hard to know what to buy and what to sell with market conditions the way they are but it looks like a good time to start nibbling on these two recent IPOs. Bausch + Lomb (NYSE: BLCO) and PepGen...